Hemp, Inc.'s Chief Visionary Consultant, Bruce Perlowin, Talks With Stock Day Podcast About Hemp, Inc.'s Super Potent Line of CBD/CBG/CBN Products

Las Vegas, NV, July 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --   After being in the industry for almost 50 years, Bruce Perlowin knows a thing or two about hemp and all that's derived from it.  From founder and CEO (of Hemp, Inc.) to now Chief Visionary Consultant, Bruce Perlowin has been a sought-after industry consultant, helping other industry companies gain a stronger foothold in the market, while continuing to help Hemp, Inc. expand its market reach.  Stock Day Podcast was lucky enough to catch up with Perlowin for an interview where he revealed a few benefits you may not know about Hemp, Inc.'s super potent line of CBD/CBG products. With cannabidiol (CBD) officially going mainstream, Hemp, Inc.'s innovative, highly potent CBD products have also garnered the attention of the media. Sever Copley, co-host of the Stock Day Podcast, introduced and welcomed its returning guest, Bruce Perlowin, as one of the industry creatives and started off the interview with Perlowin's background in the industry: "Currently, you are the CVC or Chief Visionary Consultant for Hemp, Inc. You've moved on from being the founder and CEO to being a consultant in the industry. Do you consult for other companies other than Hemp, Inc.?" "I consult with a whole variety of companies," said Perlowin.  "Traditionally, back in 2014, I made companies a lot of money because I have known this industry for 50 years. With my consulting you get me and my network of experts so whatever I don't know, they know. So yes, I consult for at least half a dozen companies right now." When asked to tell the listeners about the company's launch of CBD/CBG/CBN high potency product line, Perlowin said it "started years ago with 500 mg, in a bottle, 850 mg, 1000 mg, 1500 mg, and 2000 mg. While we were figuring out the therapeutic doses, we finally came out with a real high potency, because that's the therapeutic dose that gets the effect. We're in our late 60s and early 70s, so we formulated the products keeping ourselves in ... Full story available on Benzinga.com